Mativ Q3 2026: FAM Strength Offset by SAS Disruption, Management Sticks to Recovery Timeline

What happened

Mativ's Q3 2026 results showed a sharply divided portfolio, with consolidated sales falling 2.8% to $499.5 million and adjusted EBITDA declining to $62.3 million from $66.8 million a year earlier. The Filtration & Advanced Materials segment grew 11.6% organically to $218.5 million and expanded its adjusted EBITDA margin to 18.1%, driven by commercial space films moving into standard production. In contrast, the Sustainable & Adhesive Solutions segment saw sales drop to $281.0 million from $315.4 million, with adjusted EBITDA margin falling to 11.6% from 13.7%, pressured by tornado-related disruption, healthcare destocking, and Canadian tape tariffs. Management reiterated its expectation that SAS headwinds will normalize by early 2027 and maintained its mid-2027 net leverage target of 2.5x-3.5x, but offered no new catalysts beyond existing recovery plans. The earnings call likely reinforced the view that the company remains a two-speed story, with FAM's strength insufficient to offset SAS's near-term weakness.

Implication

The Q3 call confirmed that Filtration & Advanced Materials is the only engine of growth, while Sustainable & Adhesive Solutions remains a drag on consolidated results. Management's guidance assumes temporary headwinds fade by early 2027, but the risk is that healthcare destocking and tariff impacts persist longer than expected, delaying margin recovery. Free cash flow remained positive year-to-date, but the quarterly figure weakened from Q2, and the company must fully repay its revolver by year-end 2026 to maintain credibility. Given the current valuation at roughly 7.4x earnings and high net leverage, the stock offers limited margin of safety until SAS shows clear improvement. A more attractive entry point would be near $10.50 or when SAS adjusted EBITDA margin approaches 13.7%, which is unlikely before mid-2027.

Thesis delta

The WAIT thesis from the master report is reinforced by the Q3 call; management acknowledged the miss but did not provide new evidence that SAS recovery is accelerating. The key monitorable remains SAS margin recovery and debt reduction, and until those improve, the stock is a show-me story with balanced risk-reward.